Perpetual Medicines Launches with $8 Million Seed Round, Led by Chengwei Capital
Perpetual Medicines, a biotech firm with operations in Shanghai and Boston, has officially launched, announcing...
Takeda Reinforces Takeda Spark Incubator Program with Expanded Partnerships in China
Takeda (TYO: 4502) has reportedly renewed and expanded a series of partnerships to bolster its...
Novocure Restructures and Prioritizes Pipeline Amid Anticipated NSCLC Approval
Novocure (NASDAQ: NVCR), a Switzerland-based developer of Tumor Treating Fields (TTFields) cancer therapeutic technology that...
AbbVie’s Telisotuzumab-Vedotin Shows Promising Results in NSCLC Phase 2 Trial
AbbVie (NYSE: ABBV) has unveiled data from a Phase 2 trial of its potential first-in-class...
Boehringer Ingelheim Partners with Phenomic AI to Target Stroma-Rich Cancers
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic...
Jiangsu Hengrui Receives NMPA Approval for Esophageal Cancer and Breast Cancer Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...
Asieris Pharmaceuticals’ Hexvix for Bladder Cancer Accepted for Review by China’s NMPA
Asieris Pharmaceuticals (SHA: 688176), a specialist in urogenital cancer based in China, has announced that...
Jiangxi Jemincare’s KRAS Inhibitor Earns Breakthrough Designation from China’s CDE for NSCLC
The China Center for Drug Evaluation (CDE) website has indicated that Jiangxi Jemincare Group’s proprietary...
Eli Lilly Partners with Prism BioLab to Discover Peptide-Mimicking Small Molecule Inhibitors
Eli Lilly and Company (NYSE: LLY) has entered into a partnership with Japan-based biotechnology firm...
Roche’s Mosunetuzumab and AnHeart’s Taletrectinib Poised for Priority Review in China
The China Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Lunsumio...
China’s CDE Expands Market Approval Services with Two New Regional Windows
The China Center for Drug Evaluation (CDE) has announced the establishment of two additional external...
Sinocelltech’s PD-1 Inhibitor SCT-I10A for HNSCC Accepted for NMPA Review
Sinocelltech Group Ltd (SHA: 688520), a Chinese biopharmaceutical company, has announced that its market approval...
Bosscome Science & Technology Secures Series A Funding for Precision Medical Navigation Systems
Bosscome Science & Technology, a Chongqing-based developer of integrated optical and magnetic navigation systems, has...
NMPA Approves TINGSN Technology’s Disposable Intracardiac Ultrasound Diagnostic Catheter
The National Medical Products Administration (NMPA) has granted market approval to TINGSN Technology, a China-based...
Everest Medicines’ Nefecon NDA for IgAN Accepted for Review in South Korea
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the New Drug Application...
ClouDr Partners with Yangtze River Pharmaceutical to Digitize Chronic Disease Marketing
Hangzhou Kang Ming Information Technology Co., Ltd, trading as “ClouDr” (HKG: 9955), has entered into...
CAR T-Cell Therapy Stocks Plunge as FDA Investigates Cancer Reports Linked to Treatments
Shares of Chimeric Antigen Receptor (CAR) T cell therapy companies plummeted on November 28, 2023,...
Pfizer Enters Strategic Alliance with Guangdong Government to Boost Biomedicine R&D
Pfizer (NYSE: PFE), the US pharmaceutical powerhouse, has signed a strategic memorandum of understanding with...
Bayer Partners with Hurdle to Launch Saliva-Based Age Tests in Global E-Commerce
Bayer (ETR: BAYN), the German multinational, has announced a strategic collaboration to globally distribute Hurdle’s...
Merck’s V116 Pneumococcal Vaccine Shows Promising Data Against Pfizer’s Prevnar 20
Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled new data from a late-stage trial...